Fundraising FoxImmuneel
3 known investors
Find your way into Immuneel
Sign up to see every warm intro you have to Immuneel
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Immuneel team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Immuneel Therapeutics develops and manufactures cell-based immunotherapies, including CAR-T therapies, for cancer patients, with in-house cGMP lentiviral vector manufacturing. The company aims to make next-generation cell therapies affordable and accessible in India, with a global outlook.
Founders & leadership
KM
Kiran Mazumdar-ShawBoard Director & Co-founder
SM
Siddhartha MukherjeeBoard Director & Co-founder
AM
Amit MookimAmit Mookim is co-founder of Immuneel Therapeutics, which develops cell-based immunotherapies including CAR-T treatments for cancer patients with in-house manufacturing capabilities.
Investors · 3
F-Prime Capitallisted by F-Prime CapitalCambridge · $3M – $10M
How we know: F-Prime Capital's portfolio page · Not right? Tell us
Vedanta Capitallisted by Vedanta CapitalNew York
How we know: Vedanta Capital's portfolio page · Not right? Tell us
RainmatterreportedBengaluru · $60K – $12M
How we know: funding news · press coverage · Not right? Tell us
Related companies · 5
LyellLyell develops CAR T-cell therapies for cancer patients by leveraging deep expertise in T-cell biology and oncology. The company operates an integrated pipeline spanning discovery through manufacturing and clinical trials, with its own manufacturing facility in Washington.
AlumniAstraZeneca develops and markets pharmaceutical products, vaccines, and biologics across oncology, cardiovascular disease, respiratory and immunology, and rare disease areas, serving patients and healthcare providers globally.
LinkcelltxLink Cell Therapies is a biotechnology company developing logic-gate LINK CAR-T cell therapies aimed at treating solid and liquid tumors. It works in the cancer immunotherapy space and has a strategic collaboration with Johnson & Johnson.
Artielle ImmunotherapeuticsArtielle Immunotherapeutics develops DRhQ, a therapeutic platform that targets the CD74 receptor and inhibits macrophage migration inhibitory factor (MIF) to treat neuroinflammatory conditions such as progressive multiple sclerosis and advanced cancers. The company builds on research from OHSU and the VA Portland Healthcare System.
Rigel PharmaceuticalsRigel is a biopharmaceutical company that develops and markets therapies including olutasidenib, pralsetinib, and fostamatinib for conditions such as acute myeloid leukemia and chronic immune thrombocytopenia. This page invites investigator-sponsored research proposals, offering study drug and/or monetary grants for independent studies aligned with Rigel's therapeutic areas.
Companies working in the same space as Immuneel.
Frequently asked questions
- What does Immuneel do?
- Immuneel Therapeutics develops and manufactures cell-based immunotherapies, including CAR-T therapies, for cancer patients, with in-house cGMP lentiviral vector manufacturing. The company aims to make next-generation cell therapies affordable and accessible in India, with a global outlook.
- Who founded Immuneel?
- Immuneel was founded by Kiran Mazumdar-Shaw, Siddhartha Mukherjee.
- Who are Immuneel's investors?
- Immuneel's investors include F-Prime Capital, Vedanta Capital, Rainmatter.